Lipocine Inc. (LPCN), a biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted Fast ...

LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...

LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the POC ...

According to National Institutes of Health, decompensated cirrhosis is an acute deterioration in liver function in a patient with cirrhosis. Fast Track Designation provides several benefits ...

Sarcopenia is a common complication of decompensated cirrhosis resulting in progressive loss of muscle mass and function. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

In addition, the accuracy of MELD scores in predicting the natural history of patients with decompensated HBV cirrhosis has not been prospectively determined. Because the natural history of ...

The incidence of liver adverse events (cirrhosis, hepatic decompensation, and hepatocellular carcinoma) and non-liver adverse events (cardiovascular diseases, chronic kidney disease, and non–sex ...

Serious liver injury has been reported in patients with primary biliary cholangitis (PBC) without cirrhosis being treated ... due to reports of hepatic decompensation and failure among PBC ...